Ladenburg Thalmann upgraded PaySign from Sell to Neutral and set a new price target of $3.50
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $6.00 | Buy | Lake Street |
| 3/30/2022 | $4.00 | Mkt Perform | Barrington Research |
| 3/24/2022 | Buy → Neutral | Ladenburg Thalmann | |
| 8/20/2021 | $3.50 | Neutral → Buy | DA Davidson |
| 8/19/2021 | Neutral → Buy | DA Davidson | |
| 8/12/2021 | $3.50 → $3.75 | Neutral → Buy | Ladenburg Thalmann |
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
Garcia Tapped to Lead Strategy for Company's Life Science Solutions Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management software platforms and integrated payment processing for the life sciences industries, today announced that it has appointed Jose Garcia as Executive Vice President, Life Science Solutions. In his new role at Paysign, Mr. Garcia will implement and execute the market strategy for the company's comprehensive suite of engagement and management solutions targeting the life sciences industries. With more than two decades of executive experience in life sciences services, Mr. Garcia is a
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced the opening of a new 30,000 square foot patient service support center in Henderson, Nevada. The facility increases Paysign's support capacity fourfold and will bolster the company's rapidly growing patient affordability business. The expansion reflects Paysign's strategic focus on scaling operations to meet rapidly growing demand from pharmaceutical manufacturers seeking more effective patient affordability solutions. This demand is being driven by Paysign's
Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced they will be attending the ninth annual Lake Street Best Ideas Growth BIG9 Conference to be held Thursday, September 11, 2025. The conference is an annual invitation-only event, featuring dynamic, small-cap companies interacting with top institutional investors. The format has been designed to give attendees direct access to senior management via one-on-one and group meeting formats. Paysign's Chief Financial Officer, Jeff Baker, will be presenting to inves
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
4 - Paysign, Inc. (0001496443) (Issuer)
8-K - Paysign, Inc. (0001496443) (Filer)
8-K - Paysign, Inc. (0001496443) (Filer)
Lake Street initiated coverage of PaySign with a rating of Buy and set a new price target of $6.00
Barrington Research initiated coverage of PaySign with a rating of Mkt Perform and set a new price target of $4.00
Ladenburg Thalmann downgraded PaySign from Buy to Neutral
Second quarter 2025 total revenues of $19.08 million, up 33.1% from second quarter 2024 Second quarter 2025 net income of $1.39 million, up 99.1% from $697 thousand a year ago, while diluted earnings per share was $0.02, versus $0.01 for second quarter 2024 Second quarter 2025 Adjusted EBITDA of $4.51 million, up 101.8% from $2.24 million a year ago, while diluted Adjusted EBITDA per share was $0.08 versus $0.04 for second quarter 20241 Added 123 net plasma centers during second quarter 2025, all which went live June 16. We exited the quarter with 607 centers; average monthly revenue per plasma center decreased to $7,098 compared to $7,916 for the same period last year; year-over-
First quarter 2025 total revenues of $18.60 million, up 41.0% from first quarter 2024 First quarter 2025 net income of $2.59 million, or diluted earnings per share of $0.05, versus net income of $309 thousand, or diluted earnings per share of $0.01, for first quarter 2024 First quarter 2025 Adjusted EBITDA of $4.96 million, up 193.3% from $1.69 million a year ago, while diluted Adjusted EBITDA per share was $0.09 versus $0.03 for first quarter 20241 Total plasma center count increased by four net centers during first quarter 2025, exiting the quarter with 484 centers; revenue per plasma center decreased to $6,517 compared to $7,414 for the same period last year; year-over-year plasma
For the Full-Year Full-year 2024 total revenues of $58.38 million, up 23.5% from full-year 2023 Full-year 2024 net income of $3.82 million, or diluted earnings per share of $0.07, versus net income of $6.46 million, or diluted earnings per share of $0.12 for full-year 2023 Full-year 2024 Adjusted EBITDA of $9.62 million, up 43.3% from $6.71 million a year ago, while diluted Adjusted EBITDA per share was $0.17 versus $0.12 for full-year 20231 Total plasma center count increased by 16 during 2024, exiting the year with 480 centers, contributing to a 4.6% increase in plasma revenue versus the same period last year Added 33 net patient affordability programs during 2024, exiting the y
Garcia Tapped to Lead Strategy for Company's Life Science Solutions Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management software platforms and integrated payment processing for the life sciences industries, today announced that it has appointed Jose Garcia as Executive Vice President, Life Science Solutions. In his new role at Paysign, Mr. Garcia will implement and execute the market strategy for the company's comprehensive suite of engagement and management solutions targeting the life sciences industries. With more than two decades of executive experience in life sciences services, Mr. Garcia is a
Paysign Strengthens Leadership in Technology for Plasma and Pharmaceutical Industries Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced that it has acquired the assets of Gamma Innovation LLC (Gamma), significantly enhancing Paysign's capabilities in plasma donor and pharmaceutical patient engagement technologies. As part of this strategic acquisition, Paysign has appointed Michael Ngo, former Managing Member of Gamma, as its Chief Innovation Officer. "This acquisition represents an exciting milestone for Paysign as we accelerate our growth strategy and expand our
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)
SC 13G/A - Paysign, Inc. (0001496443) (Subject)